Can a common spice tame Asthma's airway inflammation?
NCT ID NCT07792395
First seen Aug 28, 2026 · Last updated Aug 28, 2026
Summary
This phase 2 trial tests whether daily ginger extract capsules can improve airway responsiveness and reduce inflammation in adults with asthma. Participants with mild to severe persistent asthma, despite using inhaled corticosteroids, will receive either ginger extract or a placebo for a set period. Researchers will measure changes in lung function, markers of inflammation, and asthma symptoms. The goal is to see if ginger could serve as a useful add-on to standard asthma care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Ginger extract taken as a daily capsule
- What this could lead to
- If ginger extract improves airway responsiveness and reduces inflammation, it could become a complementary add-on treatment for people with asthma.
- What could go wrong
- This is a small early-phase trial with only 32 participants, so results may not apply broadly. Ginger may also cause digestive upset or interact with other medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 32 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults aged 18 years or older with mild to severe persistent asthma as defined by NIH National Asthma Education and Prevention Program (NAEPP) guidelines, with asthma that is not optimally controlled despite current use of inhaled corticosteroids with or without inhaled long-acting beta agonists. 2. Treatment with inhaled corticosteroids (ICS), with or without long-acting beta-agonists/long-acting muscarinic antagonists and montelukast. 3. Physician-diagnosed asthma confirmed by history/report, pulmonary function testing with FEV1 ≥60% predicted or ≥1.5 L, and methacholine testing with baseline methacholine PD20 \<16 mg/mL if taking ICS or \<8 mg/mL if not taking ICS at Visit 2. 4. Non-smoker of tobacco, e-cigarettes, or marijuana for ≥1 year. Nicotine patch or gum is permitted. 5. Smoking history of ≤10 pack-years. 6. Suboptimal asthma control as determined by an Asthma Control Test (ACT) score ≤19 at the Screening and Randomization Visits. 7. Ability to understand English or Spanish, understand the study procedures, and comply with them f r the entire study period. 8. Participants of childbearing potential must have negative urine pregnancy testing as required by the protocol and agree to use effective contraception during the trial. Exclusion Criteria: 1. Major chronic illness that, in the judgment of the study physician, would interfere with study participation, including non-skin cancer, uncontrolled diabetes mellitus, coronary artery disease, congestive heart failure, stroke, severe hypertension, renal failure, liver disorders, malabsorption disorders, immunodeficiency states, major neuropsychiatric disorders, or seizure disorders. 2. Cardiovascular conditions including myocardial infarction or stroke within the previous 3 months, uncontrolled hypertension, or known aortic aneurysm. 3. History of physician-diagnosed chronic bronchitis, emphysema, or COPD. 4. Current use of ginger supplements. 5. Oral corticosteroid use within the previous 6 weeks. 6. Use of an investigational treatment within the previous 30 days. 7. Use of anticoagulants, such as warfarin, rivaroxaban, or similar agents. 8. Known adverse reaction to ginger or ginger products. 9. Cancer other than skin cancer. 10. Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. 11. Inability or unwillingness to provide written informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Asthma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Columbia University Asthma Center
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single triple inhaler tame asthma in the real world?
- Can a Three-Drug inhaler outperform the standard Two-Drug treatment for asthma?
- Can a new inhaler match Symbicort's performance?
- Fine-Mist inhalers aim to reach deep lungs in COPD
- Can a hormone supplement tame asthma?
- A wearable stethoscope may let kids with asthma monitor their lungs at home